Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-38583 for Tear Eosinophil Reduction in Allergic Conjunctivitis
NCT00881673Phase 2Withdrawn
- Sponsor
- Alcon Inc.
- Start
- May 2009
- Primary completion
- May 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cilomilast in allergic conjunctivitis (AC) (3 arms), sponsored by Alcon Inc. Primary endpoint: Mean change in tear eosinophil level at Visit 7 post-CAC from Visit 2 post-CAC at 15 days. Planned start May 2009; status: withdrawn.
02
Drugs
cilomilast
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00881673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881673.